Skip to content

Study · Randomized controlled trial · n = 47 · 2001

2 results

A randomized controlled trial of goserelin and medroxyprogesterone acetate in the treatment of pelvic congestion.

Soysal ME, Soysal S, Vicdan K, Ozer S

Human reproduction (Oxford, England)1 May 2001Cited by 103 (Europe PMC)

PMID11331640 (opens in a new tab)DOI10.1093/humrep/16.5.931 (opens in a new tab)PepBankPUB-11331640
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with pelvic congestion syndrome, goserelin produced greater pelvic venographic improvement than MPA at 1 year after treatment.

    In plain wordsIn patients with pelvic congestion syndrome, goserelin improved pelvic venograms more than MPA at 1 year after treatment.

    Peptide
    Goserelin
    Outcome
    IncreasePelvic venographic improvement
    Study

    n = 47

    Comparator
    medroxyprogesterone acetate
    Outcome group
    Pelvic congestion · Reproductive and sexual health
    Studied dose
    3.6 mg/month · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    At 1 year after treatment, goserelin remained superior to MPA in terms of pelvic venographic improvement as an objective measure.
    2 context sentences
    Summary · context
    in a prospective randomized trial in 47 patients with pure pelvic congestion syndrome.
    Summary · context
    Patients received either goserelin acetate (3.6 mg/month for 6 months) or medroxyprogesterone acetate (MPA; 30 mg/day for 6 months).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In pelvic congestion syndrome, goserelin improved signs, symptoms, sexual functioning, anxiety and depressive states more than MPA (P = 0.0001).

    In plain wordsIn pelvic congestion syndrome, goserelin improved symptoms, sexual functioning, anxiety and depressive states more than MPA.

    Peptide
    Goserelin
    Outcome
    MixedSymptoms, sexual function and psychological states
    Study

    n = 47

    Comparator
    medroxyprogesterone acetate
    Outcome group
    Pelvic congestion · Reproductive and sexual health
    Studied dose
    3.6 mg/month · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    In alleviation of signs and symptomatology, improvement of sexual functioning and reduction of anxiety and depressive states as subjective measures, goserelin acetate achieved a statistically significant advantage (P = 0.0001) compared with MPA.
    2 context sentences
    Summary · context
    in a prospective randomized trial in 47 patients with pure pelvic congestion syndrome.
    Summary · context
    Patients received either goserelin acetate (3.6 mg/month for 6 months) or medroxyprogesterone acetate (MPA; 30 mg/day for 6 months).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.